FDA nod for Roche drug expands its use to babies with spinal muscular atrophy May 31, 2022 Auto Bot BioPharma, Clinical Trials, Legal, News, Pharma, PTC Therapeutics, Rare diseases, Roche, spinal muscular atrophy, Switzerland 0 Roche drug Evrysdi, one of three FDA-approved treatments for spinal muscular atrophy, is now approved for treating those younger than age 2. The regulatory decision puts the oral drug on equal footing with SMA drugs from Novartis and Biogen.